Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from EXACT Therapeutics AS ( (DE:56F) ) is now available.
EXACT Therapeutics has been granted a patent in the United Kingdom for its Acoustic Cluster Therapy (ACT®) aimed at treating central nervous system diseases, including brain conditions. This milestone is significant as it addresses the challenge of the blood-brain barrier, potentially enabling more effective treatments for conditions like glioblastoma, the most common form of brain cancer.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that leverages ultrasound and microbubbles for targeted drug delivery in oncology. Their proprietary Acoustic Cluster Therapy (ACT®) is designed to enhance the delivery of therapeutic agents, particularly in oncology and brain diseases. The company’s shares are listed on Euronext Growth Oslo.
Average Trading Volume: 8,981
Current Market Cap: NOK172.1M
Find detailed analytics on 56F stock on TipRanks’ Stock Analysis page.